Profile cover photo
Profile photo
Galectin Therapeutics
5 followers -
Combating Fatty Liver Disease & Liver Fibrosis
Combating Fatty Liver Disease & Liver Fibrosis

5 followers
About
Galectin Therapeutics's posts

Post has attachment
Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis - http://buff.ly/2djOlaV

Research to be presented at The Liver Meeting® 2016 demonstrates correlation of FibroScan and MRE as non-invasive tests to assess the progression of liver fibrosis and cirrhosis

Read More:

Post has attachment
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis

Read more: http://buff.ly/2dq1rro

Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled

Closed private placement financing for $1.5 million

Conference call to be held today at 5:30 p.m. (Eastern Time)

Read more: http://buff.ly/2cAUkeT

Post has attachment
Galectin Therapeutics to Present TODAY at Rodman & Renshaw 18th Annual Global Investment Conference, view here:

Post has attachment
Cracking the Enigma of Fatty Liver Disease - http://buff.ly/2bGdw8Y

Approved Pharmacologic Treatments for NAFLD, NASH, and Cirrhosis Are Desperately Needed

Post has attachment

Post has attachment
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial - http://buff.ly/2bPOvGV

Meaningful activity of GR-MD-02 in treating psoriasis suggests promise in treatment of non-alcoholic steatohepatitis (NASH), the company's primary target

Learn more:

Post has attachment
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update - http://buff.ly/2axgRbr

Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September. Australian patent allowance strengthens global intellectual property franchise.

Post has attachment
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis - http://buff.ly/2b0tSHG

"We are pleased that patient recruitment in our NASH-CX trial was completed ahead of our original expectations," said Peter G. Traber, M.D., Galectin's president, chief executive officer and chief medical officer.

Post has attachment
Bret Jensen's latest article on Seeking Alpha, "Some Potential NASH Plays," includes Galectin Therapeutics (NASDAQ: GALT) as one the companies positioned to address the health risks associated with the growing problem of fatty liver disease.

Read the article here:

Post has attachment
Fatty Liver is an Enormous Global Problem - http://buff.ly/29SaZY6

I often write about fatty liver disease, a problem that is gaining mainstream recognition as published earlier this year in Newsweek. It is easy to assume that this is a problem just in the U.S., but data are coming in that highlight it as a global problem, as published in a recent article (1) and an accompanying editorial(2) in the journal Hepatology.

Read the entire article:
Wait while more posts are being loaded